First human treatment of resistant neoplastic meningitis by intrathecal administration of MTX plus (125)IUdR.

Abstract

PURPOSE Neoplastic meningitis is often the final outcome of disseminated cancer and is rapidly lethal. Its limited treatment relies on systemic or intrathecal chemotherapy with methotrexate (MTX) or thiotepa. When 5-iodo-2'-deoxyuridine labeled with (125)I ((125)IUdR) is incorporated into the DNA of mitotic tumor cells, the Auger electrons emitted during… (More)
DOI: 10.1080/09553000802395535

Topics

Cite this paper

@article{Rebischung2008FirstHT, title={First human treatment of resistant neoplastic meningitis by intrathecal administration of MTX plus (125)IUdR.}, author={Christine Rebischung and Dieter Hoffmann and Luciana Cadore Stefani and M D Desruet and K Wang and S. James Adelstein and Xavier Artignan and F. Vincent and Anne Sophie Gauchez and H. Zhang and Daniel Fagret and Jean Philippe Vuillez and Amin I. Kassis and Jacques Balosso}, journal={International journal of radiation biology}, year={2008}, volume={84 12}, pages={1123-9} }